Figure 1
BCG treatment in subcutaneous bladder tumor. (A) Scheme of the BCG treatment in a heterotopic (subcutaneous) syngeneic tumor model with MB49 bladder tumor cells in female C57BL/6 mice. MB49 cells (5 × 105 cells) were subcutaneously injected on the right flank. After 24 h of tumor injection, mice received the first intratumoral treatment with BCG (8 × 106 CFU) or PBS (Mock). The treatments were performed every 7 days (total three doses) and the tumor volume was evaluated once a week using a digital caliper. Mice were euthanized and the tumors removed after 22 days post-tumor injection. (B) Representative image of the BCG or Mock treatment effect in subcutaneous bladder tumor (Scale bar, 10 mm). Tumor growth curves (C) and the final volumes after 22 days (D) are shown. Figures (C) and (D) represents the tumor volumes mean and standard deviation summary of C57BL/6 WT control animals from the following in vivo experiments comparing WT and KO mice. ****Statistically significant compared to mock, P ≤ 0.0001.
